Empagliflozin adjunct with insulin pump therapy enhanced glycemic control and β-cell function in patients with long-standing type 2 diabetes

Key Points

• This research aims to evaluate the impact of empagliflozin combined with insulin pump therapy on glycemic control and β-cell function in long-standing type 2 diabetes.
• Clinical evaluation of patients with long-standing type 2 diabetes receiving insulin pump therapy.
• Assessment of glycemic control metrics before and after the addition of empagliflozin.
• Analysis of β-cell function through relevant biomarkers.
• Significant improvement in glycemic control observed in patients after empagliflozin introduction.
• Enhanced β-cell function was noted alongside improved glycemic metrics.
• The combination therapy indicated a positive effect on managing long-standing type 2 diabetes.